All articles tagged with #immune checkpoint inhibitors
Originally Published 2 months ago — by bioengineer.org
Researchers at MD Anderson Cancer Center presented at ESMO 2025 that mRNA COVID-19 vaccines significantly boost the efficacy of cancer immunotherapy, especially in tumors with low baseline immune activity, by enhancing immune responses and increasing tumor susceptibility to checkpoint blockade, potentially transforming cancer treatment protocols.
Originally Published 6 months ago — by The Japan Times
Researchers in Japan have identified a new gut bacteria strain, YB328, that enhances the effectiveness of certain anticancer immunotherapy drugs, potentially improving treatment outcomes for more patients.
Originally Published 2 years ago — by Medical Xpress
Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment and found a way to deliver immunotherapy's cancer-killing impact without the unwelcome side effect of colitis. They discovered that colitis developed due to the composition of the gut microbiota, which caused immune T cells to be hyper-activated while regulatory T cells that put the brakes on T cell activation were deleted in the gut. By removing a specific domain in the immune checkpoint antibodies, they were able to achieve a strong anti-tumor response without inducing colitis. This work provides a potential solution to prevent colitis while preserving the anti-tumor effect of immunotherapy.